How Aging Affects the Body: The Science of Growing Older

Cellular Mechanisms of Aging

At the molecular level, nine hallmarks of aging have been identified that interact and reinforce each other. Telomere shortening occurs because DNA polymerase cannot fully replicate chromosome ends, causing telomeres (protective repetitive sequences capping each chromosome) to shorten by 50 to 200 base pairs with each cell division. When telomeres reach a critical length (approximately 4 to 6 kilobases), cells enter replicative senescence and permanently stop dividing. Genomic instability accumulates as DNA repair mechanisms become less efficient with age, with somatic mutations increasing at a rate of roughly 40 new mutations per cell per year in human tissues, eventually disrupting gene function in critical pathways.

Cellular senescence (the permanent arrest of cell division in damaged or stressed cells) increases with age, and while senescent cells represent only a small fraction of total tissue cells (estimated 1 to 15% depending on tissue and age), they secrete a cocktail of inflammatory cytokines, proteases, and growth factors called the senescence-associated secretory phenotype (SASP) that damages surrounding tissue, promotes inflammation, and can induce senescence in neighboring cells. This "contagious" senescence creates a positive feedback loop that accelerates tissue aging. Senolytic drugs that selectively eliminate senescent cells have shown remarkable effects in animal models, extending healthspan by 25 to 30% in mice, and several are now in human clinical trials for age-related conditions.

Mitochondrial dysfunction reduces cellular energy production efficiency with age. Mitochondrial DNA (which lacks the repair mechanisms protecting nuclear DNA) accumulates mutations at 10 to 17 times the rate of nuclear DNA, progressively impairing electron transport chain function. This reduced efficiency both decreases ATP availability and increases reactive oxygen species (ROS) production, creating a vicious cycle of oxidative damage to proteins, lipids, and DNA. By age 70, mitochondrial ATP production capacity has declined by approximately 50% in skeletal muscle compared to age 20, directly contributing to age-related fatigue, exercise intolerance, and muscle weakness.

Epigenetic alterations change gene expression patterns without altering DNA sequence. DNA methylation patterns, which regulate which genes are active in each cell type, become increasingly disordered with age: genes that should be silenced become active, and genes that should be active become silenced. This "epigenetic drift" erodes cell identity and function. The rate of epigenetic aging (measured by "epigenetic clocks" that assess methylation at specific CpG sites) varies between individuals and is influenced by lifestyle factors, with smoking, obesity, and chronic stress accelerating epigenetic age, while exercise, caloric restriction, and social connection slow it.

Cardiovascular Aging

The heart and blood vessels undergo progressive structural and functional changes that reduce cardiovascular reserve. Arterial walls stiffen with age as elastin fibers fragment and are replaced by collagen, while cross-linking of collagen by advanced glycation end-products (AGEs) further reduces compliance. Aortic pulse wave velocity (a measure of arterial stiffness) increases approximately 1 meter per second per decade after age 30, raising systolic blood pressure by approximately 5 to 7 mmHg per decade because the stiff aorta cannot stretch to absorb the ventricular ejection pulse. This progressive isolated systolic hypertension increases left ventricular workload, promoting compensatory hypertrophy (the heart wall thickens by about 1 mm per decade after age 30).

Maximum heart rate declines predictably with age (approximately 220 minus age, though individual variation is substantial), reducing maximum cardiac output by roughly 1% per year. The heart's response to sympathetic stimulation diminishes due to decreased beta-adrenergic receptor density, meaning the aging heart cannot increase rate and contractility as effectively during exercise or stress. Diastolic function declines as the left ventricle stiffens and relaxes more slowly between beats, which is why heart failure with preserved ejection fraction (HFpEF, where the heart squeezes normally but fills poorly) becomes increasingly common after age 65.

VO2max (maximum oxygen consumption, the gold standard measure of cardiovascular fitness) declines approximately 10% per decade after age 30 in sedentary individuals, driven by both central factors (reduced maximum cardiac output) and peripheral factors (reduced muscle mass and mitochondrial density). However, lifelong exercisers preserve VO2max at levels 20 to 30 years "younger" than sedentary age-matched peers, demonstrating that much of "normal" cardiovascular aging reflects physical inactivity rather than inevitable biological decline.

Musculoskeletal Aging

Skeletal muscle mass peaks in the late 20s to early 30s and then declines approximately 3 to 8% per decade after age 30, accelerating to 5 to 10% per decade after age 50 (a process termed sarcopenia). This loss is selective: Type II (fast-twitch) fibers atrophy preferentially while Type I (slow-twitch) fibers are relatively preserved, explaining why aging reduces power and speed disproportionately to endurance. Motor unit remodeling contributes: motor neurons die with age (approximately 1% per year after age 60), and denervated fast-twitch fibers are re-innervated by surviving slow-motor neurons, effectively converting them to slow-twitch phenotype. By age 80, the number of motor units in the biceps has declined by approximately 50%.

Bone density peaks around age 25 to 30, then declines at approximately 0.5 to 1% per year, with an accelerated phase in women during the 5 to 10 years following menopause (losing 2 to 3% annually) as estrogen withdrawal removes its inhibitory effect on osteoclast activity. By age 80, women have typically lost 30 to 50% of their peak bone mass and men 20 to 30%. This loss is not uniform: trabecular bone (the spongy interior of vertebrae, pelvis, and long bone ends) is lost faster than cortical bone (the dense outer shell), explaining why vertebral compression fractures and hip fractures at the femoral neck are the hallmark injuries of osteoporosis.

Articular cartilage, which lacks blood supply and has minimal regenerative capacity, accumulates wear damage over decades. Proteoglycan content decreases (reducing the cartilage's ability to attract and hold water for shock absorption), collagen network integrity degrades, and chondrocyte function declines. By age 65, over 80% of individuals show radiographic evidence of osteoarthritis in at least one joint, though only about 60% are symptomatic. The combination of cartilage thinning, osteophyte (bone spur) formation, and synovial inflammation constitutes osteoarthritis, the most common chronic joint disease worldwide.

Neurological Aging

Brain volume decreases approximately 5% per decade after age 40, with the frontal cortex and hippocampus (regions critical for executive function, decision-making, and memory formation) shrinking most rapidly. This volume loss reflects both neuronal death and white matter tract degeneration (demyelination and axonal loss that slows neural transmission by 10 to 15% between ages 30 and 80). Processing speed, the rate at which the brain handles information, declines steadily from the early 20s, dropping approximately 20% by age 60 and 40% by age 80 compared to peak performance.

Working memory capacity (the ability to hold and manipulate information in mind) and episodic memory (recalling specific events) decline with age, while semantic memory (general knowledge) and procedural memory (motor skills) are relatively preserved. The hippocampus loses approximately 1 to 2% of its volume per year after age 50, with faster rates in individuals carrying the APOE4 allele (a genetic risk factor for Alzheimer's disease). Neurogenesis (new neuron production) in the hippocampal dentate gyrus continues throughout life but at declining rates, from roughly 700 new neurons per day at age 20 to fewer than 100 per day by age 70.

Neurotransmitter systems decline unevenly: dopamine (critical for movement, reward, and motivation) decreases approximately 10% per decade from early adulthood, contributing to slower movements, reduced motivation, and increased Parkinson's disease risk. Acetylcholine (essential for memory and attention) production declines in the basal forebrain, with severe cholinergic loss being a hallmark of Alzheimer's disease. Serotonin receptor density decreases, potentially contributing to sleep disturbances and mood changes in older adults. These neurochemical changes interact with structural decline to produce the characteristic cognitive profile of aging: slower but often wiser, with difficulty learning new information but retained expertise and judgment.

Immune System Aging (Immunosenescence)

The immune system undergoes profound changes with age that increase susceptibility to infection, reduce vaccine effectiveness, and promote chronic low-grade inflammation. The thymus, which produces and educates T cells, begins involuting (shrinking and being replaced by fat) after puberty and is 90% replaced by age 50, dramatically reducing the output of new naive T cells. The remaining T cell repertoire becomes increasingly dominated by memory cells specific to previously encountered pathogens, leaving fewer naive cells available to respond to novel threats. This explains why older adults are more vulnerable to new infections (like novel influenza strains or COVID-19) and respond poorly to vaccines (influenza vaccine effectiveness drops from 70 to 90% in young adults to 30 to 40% in those over 65).

"Inflammaging," a state of chronic, low-grade systemic inflammation in the absence of infection, develops with age as senescent cells accumulate (secreting inflammatory SASP factors), gut barrier integrity declines (allowing bacterial products to enter the bloodstream), and immune regulation weakens. Circulating levels of inflammatory markers (IL-6, TNF-alpha, CRP) increase 2 to 4-fold between ages 30 and 70. This persistent inflammation drives age-related diseases: it promotes atherosclerotic plaque formation, insulin resistance, neurodegeneration, cancer cell survival, and muscle protein breakdown. Anti-inflammatory interventions (exercise, caloric restriction, specific dietary patterns, and potentially targeted drugs) that reduce inflammaging biomarkers correlate with improved healthspan in observational studies.

What Slows Aging: Evidence-Based Interventions

Caloric restriction (reducing caloric intake by 20 to 30% without malnutrition) extends lifespan by 20 to 50% in every organism tested, from yeast and worms to rodents and possibly primates. The CALERIE trial (2 years of 25% caloric restriction in healthy humans) demonstrated reduced inflammatory markers, improved insulin sensitivity, decreased thyroid hormones (indicating lower metabolic rate), and slowed epigenetic aging. Proposed mechanisms include activation of sirtuins (NAD+-dependent deacetylases that promote DNA repair and stress resistance), AMPK pathway activation (sensing low energy and promoting cellular maintenance), reduced mTOR signaling (shifting cellular resources from growth to repair), and decreased insulin/IGF-1 signaling.

Exercise is the most potent anti-aging intervention accessible to most people. Regular moderate exercise (150+ minutes per week) is associated with 7 to 10 years of delayed biological aging based on telomere length, epigenetic clock measurements, and functional capacity. At the cellular level, exercise promotes mitochondrial biogenesis (counteracting the age-related decline in mitochondrial density), activates autophagy (cellular cleanup of damaged proteins and organelles), increases BDNF (brain-derived neurotrophic factor, promoting neuroplasticity and hippocampal neurogenesis), and reduces chronic inflammation. The dose-response relationship is roughly linear up to about 3 to 5 times the minimum recommended activity level, after which additional benefit plateaus.

Pharmaceutical approaches to aging are advancing rapidly. Metformin (a diabetes drug that activates AMPK) is being studied in the TAME trial (Targeting Aging with Metformin) for its potential to delay multiple age-related diseases simultaneously. Rapamycin and rapalogs (mTOR inhibitors) extend lifespan in mice by 10 to 15% and are being studied in companion dogs. NAD+ precursors (NMN and NR) aim to restore declining cellular NAD+ levels, though human trial results have been mixed. Senolytics (dasatinib plus quercetin, fisetin) that clear senescent cells show promise in early human trials for conditions including idiopathic pulmonary fibrosis and diabetic kidney disease. None of these have yet proven to extend human lifespan, but several demonstrably improve specific age-related biomarkers and functional outcomes.